Jia-Xin Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jia-Xin Shi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Kezhong Zhang
Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
3 shared publications Cai-Ting Gan
1 shared publication- Caiting Gan
Department of Neurology, The First Affiliated Hospital with Nanjing Medical University, 210029 Nanjing, Jiangsu, China
1 shared publication - Geng Shen
Department of Cardiology, Guangdong Cardiovascular Institute, Guangzhou, China
1 shared publication - Guanqun Wang
Department of Neurology, The First Affiliated Hospital with Nanjing Medical University, 210029 Nanjing, Jiangsu, China
1 shared publication - Heng Zhang
Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 20 November 2026
- Published by Springer Nature in npj Parkinson's Disease
Abnormal cerebellum-mediated reward processing in Parkinson’s disease with impulse control disorders: a multimodal MRI study
- 20 November 2026
- Published by Springer Nature in npj Parkinson's Disease
Open AccessAbnormal cerebellum-mediated reward processing in Parkinson’s disease with impulse control disorders: a multimodal MRI study
- Open Access
- 30 November 2025
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 24 (11) , 45203
Cortical Sulcal Depth Alterations in Parkinson’s Disease Patients With Levodopa-Induced Dyskinesia
Background: In Parkinson’s disease (PD), levodopa-induced dyskinesia (LID) represents a common motor complication of long-term dopaminergic therapy. Although levodopa remains the most effective treatment for PD, the neurological mechanisms underlying the LID remain incompletely understood. This study aimed to investigate the pattern of cortical morphological and subcortical structural alterations associated with LID in PD. Methods: Clinical data and T1-weighted structural brain images were obtained for 62 patients with PD, including 30 with LID and 32 without LID, along with 30 healthy controls (HCs). Regional sulcal depth (SD) and subcortical volumes were quantified to assess alterations in cortical surface morphology and subcortical structures. The study further aimed to evaluate the association between structural indicators and the severity of LID, as well as to determine their potential diagnostic ability. Results: PD patients with LID demonstrated reduced regional SD in the right inferior parietal and insula cortices, compared with PD patients without LID and HCs (after Bonferroni correction). The right putamen volume in both PD subtypes was lower than that of HCs (after Bonferroni correction). In particular, the level of right inferior parietal SD was negatively associated with the severity of LID (r = –0.494, p = 0.017). Receiver operating characteristic (ROC) curve analyses further revealed that the combination of cortical SD values demonstrated excellent performance in distinguishing PD-LID from PD-non-levodopa-induced dyskinesia (NLID) (area under the curve [AUC] = 0.913). Conclusions: Our main findings show that structural alterations associated with LID extend from the frontal to the parietal and insula cortices, suggesting that decreased cortical SD values in these regions may contribute to a better understanding of the neurological underpinnings of LID in PD.
- 30 November 2025
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 24 (11) , 45203
Open AccessCortical Sulcal Depth Alterations in Parkinson’s Disease Patients With Levodopa-Induced Dyskinesia
Background: In Parkinson’s disease (PD), levodopa-induced dyskinesia (LID) represents a common motor complication of long-term dopaminergic therapy. Although levodopa remains the most effective treatment for PD, the neurological mechanisms underlying the LID remain incompletely understood. This study aimed to investigate the pattern of cortical morphological and subcortical structural alterations associated with LID in PD. Methods: Clinical data and T1-weighted structural brain images were obtained for 62 patients with PD, including 30 with LID and 32 without LID, along with 30 healthy controls (HCs). Regional sulcal depth (SD) and subcortical volumes were quantified to assess alterations in cortical surface morphology and subcortical structures. The study further aimed to evaluate the association between structural indicators and the severity of LID, as well as to determine their potential diagnostic ability. Results: PD patients with LID demonstrated reduced regional SD in the right inferior parietal and insula cortices, compared with PD patients without LID and HCs (after Bonferroni correction). The right putamen volume in both PD subtypes was lower than that of HCs (after Bonferroni correction). In particular, the level of right inferior parietal SD was negatively associated with the severity of LID (r = –0.494, p = 0.017). Receiver operating characteristic (ROC) curve analyses further revealed that the combination of cortical SD values demonstrated excellent performance in distinguishing PD-LID from PD-non-levodopa-induced dyskinesia (NLID) (area under the curve [AUC] = 0.913). Conclusions: Our main findings show that structural alterations associated with LID extend from the frontal to the parietal and insula cortices, suggesting that decreased cortical SD values in these regions may contribute to a better understanding of the neurological underpinnings of LID in PD.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 19 (10) , 1321-1327
Advancements in Autologous Stem Cell Transplantation for Parkinson’s Disease
: Parkinson's disease (PD) is a progressive neurodegenerative disease marked by comparatively focal dopaminergic neuron degeneration in the substantia nigra of the midbrain and dopamine loss in the striatum, which causes motor and non-motor symptoms. Currently, pharmacological therapy and deep brain stimulation(DBS) are the primary treatment modalities for PD in clinical practice. While these approaches offer temporary symptom control, they do not address the underlying neurodegenerative process, and complications often arise. Stem cell replacement therapy is anticipated to prevent further progression of the disease due to its regenerative capacity, and considering the cost of immunosuppression and the potential immune dysfunctions, autologous stem cell transplantation holds promise as a significant method against allogeneic one to treat Parkinson's disease. In this review, the safety concerns surrounding tumorigenicity and complications associated with transplantation are discussed, along with methods utilized to evaluate the efficacy of such procedures. Subsequently, we summarize the preclinical and clinical studies involving autologous stem cell transplantation for PD, and finally talk about the benefits of autologous stem cell transplantation against allogeneic transplants.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 19 (10) , 1321-1327
Advancements in Autologous Stem Cell Transplantation for Parkinson’s Disease
: Parkinson's disease (PD) is a progressive neurodegenerative disease marked by comparatively focal dopaminergic neuron degeneration in the substantia nigra of the midbrain and dopamine loss in the striatum, which causes motor and non-motor symptoms. Currently, pharmacological therapy and deep brain stimulation(DBS) are the primary treatment modalities for PD in clinical practice. While these approaches offer temporary symptom control, they do not address the underlying neurodegenerative process, and complications often arise. Stem cell replacement therapy is anticipated to prevent further progression of the disease due to its regenerative capacity, and considering the cost of immunosuppression and the potential immune dysfunctions, autologous stem cell transplantation holds promise as a significant method against allogeneic one to treat Parkinson's disease. In this review, the safety concerns surrounding tumorigenicity and complications associated with transplantation are discussed, along with methods utilized to evaluate the efficacy of such procedures. Subsequently, we summarize the preclinical and clinical studies involving autologous stem cell transplantation for PD, and finally talk about the benefits of autologous stem cell transplantation against allogeneic transplants.
- Open Access
- 23 May 2016
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 16 (1) , 1-11
The MK2/HuR signaling pathway regulates TNF-α-induced ICAM-1 expression by promoting the stabilization of ICAM-1 mRNA
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by acute lung inflammation. Intercellular adhesion molecule-1 (ICAM-1) and interleukin-8 (IL-8) play an important role in the development of these diseases. Mitogen-activated protein kinase (MAPK) p38/activated protein kinase 2 (MK2) regulates the expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells (HPMECs) stimulated by tumor necrosis factor-α (TNF-α); however, the underlying molecular mechanism remains unclear. Here, we show that human antigen R (HuR), an RNA binding protein which binds preferentially to AU-rich elements (AREs) and stabilizes mRNAs, regulates TNF-α-induced ICAM-1 expression in the MK2/HuR signaling pathway. MK2 and HuR were silenced respectively in HPMECs and then HPMECs were stimulatied with TNF-α. Nucleo-cytoplasmic shuttling of HuR was detected by subcellular fractionation and confocal microscopy in MK2 knockdown HPMECs. In HuR silencing cells, protein and mRNA levels of ICAM-1 and IL-8 were measured by western blot analysis, ELISA and real-time PCR; mRNA stabilization were measured by real-time PCR after actinomycin D (ActD) blocking transcription. Furthermore, we performed neutrophil adhesion assay to assess the adhering capacity after HuR silencing. MK2 were subjected to a knockdown by interfering RNA, the mRNA and protein levels of HuR in human pulmonary microvascular endothelial cells (HPMECs) were not affected. However, after the stimulation of TNF-α, silencing MK2 inhibited HuR accumulation to cytoplasm from nucleus in HPMECs. Consequently, knockdown of HuR by RNA interference in HPMECs, there was reduction in the stability of ICAM-1 mRNA and ICAM-1 protein level. This event was accompanied by a decrease in the adhesion of neutrophils towards HPMECs. Nevertheless, HuR silencing had no effect on the mRNA and protein levels of IL-8. These results indicate that MK2 post-transcriptionally regulates TNF-α-induced ICAM-1 expression by altering the cytoplasmic localization of HuR in HPMECs.
- 23 May 2016
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 16 (1) , 1-11
Open AccessThe MK2/HuR signaling pathway regulates TNF-α-induced ICAM-1 expression by promoting the stabilization of ICAM-1 mRNA
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by acute lung inflammation. Intercellular adhesion molecule-1 (ICAM-1) and interleukin-8 (IL-8) play an important role in the development of these diseases. Mitogen-activated protein kinase (MAPK) p38/activated protein kinase 2 (MK2) regulates the expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells (HPMECs) stimulated by tumor necrosis factor-α (TNF-α); however, the underlying molecular mechanism remains unclear. Here, we show that human antigen R (HuR), an RNA binding protein which binds preferentially to AU-rich elements (AREs) and stabilizes mRNAs, regulates TNF-α-induced ICAM-1 expression in the MK2/HuR signaling pathway. MK2 and HuR were silenced respectively in HPMECs and then HPMECs were stimulatied with TNF-α. Nucleo-cytoplasmic shuttling of HuR was detected by subcellular fractionation and confocal microscopy in MK2 knockdown HPMECs. In HuR silencing cells, protein and mRNA levels of ICAM-1 and IL-8 were measured by western blot analysis, ELISA and real-time PCR; mRNA stabilization were measured by real-time PCR after actinomycin D (ActD) blocking transcription. Furthermore, we performed neutrophil adhesion assay to assess the adhering capacity after HuR silencing. MK2 were subjected to a knockdown by interfering RNA, the mRNA and protein levels of HuR in human pulmonary microvascular endothelial cells (HPMECs) were not affected. However, after the stimulation of TNF-α, silencing MK2 inhibited HuR accumulation to cytoplasm from nucleus in HPMECs. Consequently, knockdown of HuR by RNA interference in HPMECs, there was reduction in the stability of ICAM-1 mRNA and ICAM-1 protein level. This event was accompanied by a decrease in the adhesion of neutrophils towards HPMECs. Nevertheless, HuR silencing had no effect on the mRNA and protein levels of IL-8. These results indicate that MK2 post-transcriptionally regulates TNF-α-induced ICAM-1 expression by altering the cytoplasmic localization of HuR in HPMECs.